A cornerstone of the UK’s life science ambitions has crumbled with the announcement that drugmaker MSD is axing its under-construction £1bn research center in London. The decision is the most significant signal yet that the UK is failing to provide a stable and attractive environment for global pharmaceutical innovators.
This move is not an isolated event but part of a concerning pattern of disinvestment. US company Eli Lilly has also halted plans for a key London lab, and French firm Sanofi has cut its UK-based clinical trials in half, with its UK chief calling Britain a “terrible place to sell medicines.” The government’s vision of a thriving life sciences sector is colliding with a harsh commercial reality.
Industry leaders point to a financial framework that is no longer fit for purpose. They highlight that the UK’s spending on medicines, as a share of the total healthcare budget, is among the lowest in the developed world. This is exacerbated by a punishing “clawback” tax on revenues and drug pricing rules that have not been adjusted for inflation since 1999.
The sector is now in crisis mode, with prominent figures like scientist Sir John Bell warning that more companies are set to pull out. The pressure is mounting on the government to go beyond rhetoric and produce a credible roadmap that addresses the industry’s deep-seated concerns about pricing, spending, and overall competitiveness.